These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32539658)

  • 1. Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis.
    Romano-Aguilar M; Reséndiz-Galván JE; Medellín-Garibay SE; Milán-Segovia RDC; Martínez-Martínez MU; Abud-Mendoza C; Romano-Moreno S
    Lupus; 2020 Aug; 29(9):1067-1077. PubMed ID: 32539658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients.
    Punyawudho B; Lertdumrongluk P; Somparn P; Kittanamongkolchai W; Traitanon O; Avihingsanon Y; Vadcharavivad S
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):272-80. PubMed ID: 22456298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen.
    Reséndiz-Galván JE; Romano-Aguilar M; Medellín-Garibay SE; Milán-Segovia RDC; Niño-Moreno PDC; Jung-Cook H; Chevaile-Ramos JA; Romano-Moreno S
    Eur J Pharm Sci; 2020 Jul; 150():105370. PubMed ID: 32387086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: A population analysis.
    Yang CL; Sheng CC; Liao GY; Su Y; Feng LJ; Xia Q; Jiao Z; Xu DJ
    J Clin Pharm Ther; 2021 Dec; 46(6):1564-1575. PubMed ID: 34312870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Mathot RA
    Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.
    Yu ZC; Zhou PJ; Wang XH; Françoise B; Xu D; Zhang WX; Chen B
    Acta Pharmacol Sin; 2017 Nov; 38(11):1566-1579. PubMed ID: 28836585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.
    Zabotti A; Baraldo M; Quartuccio L; Sacco S; De Marchi G; De Vita S
    Clin Rheumatol; 2015 Jan; 34(1):171-4. PubMed ID: 25249327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis.
    Yap DYH; Tam CH; Yung S; Wong S; Tang CSO; Mok TMY; Yuen CKY; Ma MKM; Lau CS; Chan TM
    Nephrol Dial Transplant; 2020 May; 35(5):810-818. PubMed ID: 30215770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic and dose optimization of mycophenolic acid in children with anti-neutrophilic cytoplasmic antibody-associated nephritis.
    Li Z; Huang Y; Xu H; Li Z
    Eur J Clin Pharmacol; 2022 May; 78(5):831-838. PubMed ID: 35064793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus Nephritis.
    Koloskoff K; Panwar R; Rathi M; Mathew S; Sharma A; Marquet P; Benito S; Woillard JB; Pattanaik S
    Ther Drug Monit; 2024 Oct; 46(5):567-574. PubMed ID: 38723153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P; Pawiński T; Kunicki PK; Durlik M; Augustyniak-Bartosik H; Hurkacz M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):371-379. PubMed ID: 30430214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.
    Zhao W; Fakhoury M; Deschênes G; Roussey G; Brochard K; Niaudet P; Tsimaratos M; André JL; Cloarec S; Cochat P; Bensman A; Azougagh S; Jacqz-Aigrain E
    J Clin Pharmacol; 2010 Nov; 50(11):1280-91. PubMed ID: 20147615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.
    Ensom MH; Partovi N; Decarie D; Dumont RJ; Fradet G; Levy RD
    Ther Drug Monit; 2002 Apr; 24(2):310-4. PubMed ID: 11897977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.
    Zhao W; Elie V; Baudouin V; Bensman A; André JL; Brochard K; Broux F; Cailliez M; Loirat C; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2010 Apr; 69(4):358-66. PubMed ID: 20406220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L; Chen L; Liu X; Huang Z; Zheng Y; Tang K; Jiang X; Chen P
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.
    Barau C; Furlan V; Debray D; Taburet AM; Barrail-Tran A
    Br J Clin Pharmacol; 2012 Sep; 74(3):515-24. PubMed ID: 22329639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.